1月12日，春立医疗盘中下跌2.16%，截至09:39，报24.45元/股，成交871.39万元，换手率0.12%，总市 值93.78亿元。 春立医疗所属申万行业为：医药生物-医疗器械-医疗耗材。所属概念板块包括：医疗器械、小盘、H 股、融资融券、口腔医疗等。 截至9月30日，春立医疗股东户数6164.00，较上期增加4.12%；人均流通股46906股，较上期减少 3.95%。2025年1月-9月，春立医疗实现营业收入7.56亿元，同比增长48.75%；归母净利润1.92亿元，同 比增长213.21%。 分红方面，春立医疗A股上市后累计派现4.40亿元。近三年，累计派现3.90亿元。 机构持仓方面，截止2025年9月30日，春立医疗十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股295.85万股，为新进股东。中欧景气精选混合A（020876）位居第五大流通股东，持股 283.26万股，为新进股东。平安低碳经济混合A（009878）位居第八大流通股东，持股210.00万股，相 比上期减少167.00万股。南方医药保健灵活配置混合A（000452）退出十大流通股东之列。 来源：新浪证券-红岸工作室 ...

1月8日，美亚光电盘中下跌2.04%，截至13:32，报21.08元/股，成交9573.05万元，换手率1.04%，总市 值185.98亿元。 资金流向方面，主力资金净流出598.69万元，特大单买入552.55万元，占比5.77%，卖出1260.75万元， 占比13.17%；大单买入1276.91万元，占比13.34%，卖出1167.40万元，占比12.19%。 资料显示，合肥美亚光电技术股份有限公司位于安徽省合肥市高新区望江西路668号，成立日期2000年3 月3日，上市日期2012年7月31日，公司主营业务涉及 从事光电检测与分级专用设备及其应用软件研 发、生产和销售。主营业务收入构成为：色选机72.61%，医疗设备19.97%，X射线工业检测机5.25%， 配件及其他2.17%。 美亚光电所属申万行业为：机械设备-专用设备-其他专用设备。所属概念板块包括：机械、养老金概 念、MSCI中国、融资融券、口腔医疗等。 截至12月31日，美亚光电股东户数2.60万，较上期减少3.36%；人均流通股16658股，较上期增加 3.48%。2025年1月-9月，美亚光电实现营业收入16.94亿元，同比增长7.35% ...

Group 1 - The core viewpoint of the news is that Spring Medical has experienced a stock price increase of 2.05% this year, but has seen declines over the past five, twenty, and sixty trading days [2][3] - As of January 5, the stock price is reported at 23.35 yuan per share, with a total market capitalization of 8.956 billion yuan [1] - The company specializes in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implants [2] Group 2 - For the period from January to September 2025, Spring Medical achieved operating revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a year-on-year increase of 213.21% [3] - The company has distributed a total of 440 million yuan in dividends since its A-share listing, with 390 million yuan distributed over the past three years [4] - As of September 30, 2025, the number of shareholders increased by 4.12% to 6,164, while the average circulating shares per person decreased by 3.95% to 46,906 shares [3]

Core Viewpoint - Spring Medical, a leading domestic orthopedic medical device manufacturer, focuses on the research, production, and sales of implantable orthopedic medical devices, including dental metal and invisible orthodontics, and is currently in the design inspection phase for a customized porous tantalum dental implant product [2][3] Company Overview - Spring Medical is located in Tongzhou District, Beijing, and was established on February 12, 1998, with its listing date on December 30, 2021. The company specializes in implantable orthopedic medical devices, with main products including joint prosthetics and spinal implants [7][8] - The company's product range includes joint prosthetics for hip, knee, shoulder, and elbow joints, as well as a full series of spinal internal fixation systems. Its products are exported to various regions including Asia, South America, Africa, Oceania, and Europe [8] Financial Performance - For the period from January to September 2025, Spring Medical achieved operating revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a year-on-year increase of 213.21% [8] - Since its A-share listing, the company has distributed a total of 359 million yuan in dividends, with 309 million yuan distributed over the past three years [8] Market Position and Recognition - Spring Medical has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is the highest honor for small and medium-sized enterprises in China, indicating its strong innovation capability and high market share [3] - The company has obtained registration certificates for hip and knee surgical robots and medical image processing software, showcasing its investment in smart medical technology [2][3] Shareholder Information - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited and Central European Economic Selection Mixed A, both of which are new shareholders [9]

Core Viewpoint - The stock of Dengkang Oral Care has shown a year-to-date increase of 15.93%, with recent fluctuations indicating a slight decline in the short term, while the company continues to report growth in revenue and net profit [1][2]. Company Overview - Dengkang Oral Care, established on December 14, 2001, and listed on April 10, 2023, is based in Chongqing and specializes in the research, production, and sales of oral care products [1]. - The company's main revenue sources include adult toothpaste (80.43%), adult toothbrushes (9.90%), children's toothpaste (4.54%), and other oral care products [1]. Financial Performance - For the period from January to September 2025, Dengkang Oral Care achieved a revenue of 1.228 billion yuan, representing a year-on-year growth of 16.66%, and a net profit attributable to shareholders of 136 million yuan, up 15.21% year-on-year [1][2]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 8.38% to 10,600, with an average of 4,069 circulating shares per person, a decrease of 7.73% [1]. - The company has distributed a total of 344 million yuan in dividends since its A-share listing [2]. Institutional Holdings - The top circulating shareholder is Tianhong Yongli Bond A, holding 1.4526 million shares, followed by Xin'ao Quality Return Mixed Fund, which reduced its holdings by 67,400 shares [2]. - Other notable shareholders include Fuguo Consumption Theme Mixed A and Huabao Kang Consumer Products Mixed Fund, with varying changes in their holdings [2].

截至9月30日，春立医疗股东户数6164.00，较上期增加4.12%；人均流通股46906股，较上期减少 3.95%。2025年1月-9月，春立医疗实现营业收入7.56亿元，同比增长48.75%；归母净利润1.92亿元，同 比增长213.21%。 分红方面，春立医疗A股上市后累计派现3.59亿元。近三年，累计派现3.09亿元。 机构持仓方面，截止2025年9月30日，春立医疗十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股295.85万股，为新进股东。中欧景气精选混合A（020876）位居第五大流通股东，持股 283.26万股，为新进股东。平安低碳经济混合A（009878）位居第八大流通股东，持股210.00万股，相 比上期减少167.00万股。南方医药保健灵活配置混合A（000452）退出十大流通股东之列。 春立医疗今年以来股价涨95.67%，近5个交易日跌3.14%，近20日跌3.11%，近60日涨10.45%。 资料显示，北京市春立正达医疗器械股份有限公司位于北京市通州区通州经济开发区南区鑫觅西二路10 号，成立日期1998年2月12日，上市日期2021年12月30日，公司主营业务涉及北京 ...

Group 1 - The core viewpoint of the news is that Sanxiang New Materials has shown significant stock price fluctuations and performance metrics, indicating both growth and recent declines in trading activity [1][2]. Group 2 - As of November 25, Sanxiang New Materials' stock price increased by 2.04% to 31.52 CNY per share, with a total market capitalization of 13.34 billion CNY [1]. - The company has experienced a year-to-date stock price increase of 98.55%, but has seen a decline of 6.64% over the last five trading days [2]. - The company reported a revenue of 858 million CNY for the period from January to September 2025, reflecting a year-on-year growth of 0.96%, and a net profit of 77.96 million CNY, up 1.34% [2]. - The main revenue sources for Sanxiang New Materials are zirconium products (84.25%), new casting materials (11.16%), and other products (4.59%) [2]. Group 3 - Sanxiang New Materials has distributed a total of 208 million CNY in dividends since its A-share listing, with 93.76 million CNY distributed over the past three years [3]. Group 4 - As of September 30, 2025, the top ten circulating shareholders include new entrants such as China Aviation New Start Flexible Allocation Mixed A and Dongfang Alpha Industry Pioneer Mixed A, while Hong Kong Central Clearing Limited has exited the top ten [4].

Core Points - The stock price of Dongfang Zirconium has increased by 85.69% year-to-date, with a recent rise of 2.02% to 13.63 CNY per share [1] - The company has seen a net inflow of 5.68 million CNY in main funds, with significant buying and selling activity [1] - Dongfang Zirconium's main business revenue composition includes 88.92% from inorganic non-metallic zircon products [1][2] Financial Performance - For the period from January to September 2025, Dongfang Zirconium reported a revenue of 927 million CNY, a year-on-year decrease of 24.86%, while net profit attributable to shareholders increased by 193.66% to 38.68 million CNY [2] - The company has distributed a total of 30.11 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 15.95% to 128,200, with an average of 5,906 circulating shares per person, a decrease of 13.76% [2] - Hong Kong Central Clearing Limited is the third-largest circulating shareholder, holding 4.76 million shares, down by 1.90 million shares from the previous period [3]

Core Viewpoint - Oriental Zirconium's stock price has shown significant volatility, with a year-to-date increase of 84.33%, despite recent fluctuations in trading volume and net capital flow [1][2]. Group 1: Stock Performance - As of November 11, Oriental Zirconium's stock price reached 13.53 CNY per share, with a trading volume of 1.79 billion CNY and a market capitalization of 10.481 billion CNY [1]. - The stock has experienced a 4.97% increase over the last five trading days, a 5.12% decrease over the last 20 days, and a 3.84% increase over the last 60 days [1]. - The company has appeared on the "龙虎榜" (a trading board for stocks with significant trading activity) four times this year, with the most recent appearance on July 21, where it recorded a net purchase of 66.4866 million CNY [1]. Group 2: Financial Performance - For the period from January to September 2025, Oriental Zirconium reported a revenue of 927 million CNY, a year-on-year decrease of 24.86%, while the net profit attributable to shareholders was 38.6812 million CNY, reflecting a year-on-year increase of 193.66% [2]. - The company's main business revenue composition includes 88.92% from inorganic non-metallic zircon products, 6.00% from inorganic non-metallic materials, 3.18% from mineral products, 1.66% from by-products, and 0.24% from other sources [1]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Oriental Zirconium was 128,200, an increase of 15.95% from the previous period, with an average of 5,906 circulating shares per shareholder, a decrease of 13.76% [2]. - The company has cumulatively distributed 30.1102 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the third-largest, holding 4.7607 million shares, a decrease of 1.904 million shares from the previous period [3].

Group 1 - The core viewpoint of the news is that Sanxiang New Materials has shown significant stock price growth and trading activity, with a year-to-date increase of 119.28% and a recent trading volume of 2.17 billion yuan [1][2] - As of November 11, the stock price reached 34.81 yuan per share, with a market capitalization of 14.735 billion yuan [1] - The company has been actively traded, with notable net inflows and outflows of funds, indicating fluctuating investor interest [1] Group 2 - Sanxiang New Materials operates in the basic chemical industry, specifically in chemical raw materials and inorganic salts, with a focus on zirconium-based and casting modification materials [2] - For the period from January to September 2025, the company reported revenue of 858 million yuan, a year-on-year increase of 0.96%, and a net profit attributable to shareholders of 77.96 million yuan, up 1.34% [2] - The company has distributed a total of 208 million yuan in dividends since its A-share listing, with 93.76 million yuan distributed over the past three years [3] Group 3 - As of September 30, 2025, the number of shareholders increased to 33,700, with an average of 12,539 circulating shares per shareholder [2] - The top ten circulating shareholders include new entrants such as China Aviation New Start Flexible Allocation Mixed A and Dongfang Alpha Industry Pioneer Mixed A, while Hong Kong Central Clearing Limited has exited the top ten [4]